气相检测血液氢气浓度.pdf

氢在宇宙中含量丰富但空气中含量极少(0.00006 volume %也有说更低)，人的大肠内细菌可以产生氢气，目前的普遍观点认为来自肠道的氢气可能对健康有利。也有一些关于神奇治疗作用的自然泉水的传说。最近许多医学生物学领域的研究，用多种动物模型和人体试验获得许多证据，提示氢气具有十分广泛的医疗作用。尽管有许多证据说明氢气对人体是非常安全的，但呼吸、注射或饮水获得氢气对人体是否可以产生毒性作用仍需要深入研究。在研究氢气的临床效应和毒性作用时，精确测定氢气在人体内的浓度非常重要。最近来自日本的学者发表在Medical Gas Res的文章试图解决这方面的问题，文章采用气乡色谱连续检测脑缺血患者动脉和静脉血液氢气的浓度，已经各种生理指标。研究发现，呼吸1、2、4%的氢气30分钟，人体血液中氢气的浓度可以达到20uM，当停止呼吸氢气后，血液中氢气浓度迅速下降。目前临床尚未有研究证明呼吸氢气对临床疾病的治疗作用，但已经有饮用氢气水和注射氢气盐水的临床观察。呼吸氢气在临床上有其优势，这一研究给呼吸氢气治疗疾病奠定了重要基础，那就是安全性和氢气的代谢规律。

按照惰性气体的运行规律，血液中氢气的浓度改变应该符合5分钟假定时间单位的规律，那么从最高到最低浓度的变化应该持续30分钟，而这一研究的结果显示氢气的变化规律不符合理论预测。原因可能是氢气的扩散能力比较快，在短时间内体内许多组织没有饱和的情况下，血液中的浓度下降速度比较快。要证明这一规律，需要开展更长时间呼吸氢气的规律研究。

有一种感觉，过去日本蓝水星公司对科研比较热心，至少在提供水方面，许多日本学者的研究都使用该公司的产品，最近MIZ公司在氢气的研究方面非常积极，一方面体现在许多研究使用他们提供的产品，另一方面，这个公司的技术人员也积极参与科研，并独立发表相关论文。这应该是比较值得称赞的，也是国内正在追求的企业作为创新的主体的愿望。

A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 level

Hirohisa Ono

Background

In animal experiments, use of molecular hydrogen ( H2) has been regarded as quite safe and

effective, showing benefits in multiple pathological conditions such as ischemia-reperfusion

injury of the brain, heart, kidney and transplanted tissues, traumatic and surgical injury of the  brain and spinal cord, inflammation of intestine and lung , degenerative striatonigral tissue and also in many other situations. However, since cerebral ischemia patients are in old age group, the safety information needs to be confirmed. For the feasibility of H2 treatment in these patients, delivery of H2 by inhalation method needs to be checked for consistency.

Methods Hydrogen concentration (HC) in the arterial and venous blood was measured by gas

chromatography on 3 patients, before, during and after 4%(case 1) and 3%(case2,3) H2 gas

inhalation with simultaneous monitoring of physiological parameters. For a consistency

study, HC in the venous blood of 10 patients were obtained on multiple occasions at the end

of 30-min H2 inhalation treatment.

Results

The HC gradually reached a plateau level in 20 min after H2 inhalation in the blood, which

was equivalent to the level reported by animal experiments. The HC rapidly decreased to

10% of the plateau level in about 6 min and 18 min in arterial and venous blood, respectively

after H2 inhalation was discontinued. Physiological parameters on these 3 patients were

essentially unchanged by use of hydrogen. The consistency study of 10 patients showed the

HC at the end of 30-min inhalation treatment was quite variable but the inconsistency

improved with more attention and encouragement.

Conclusion

H2 inhalation of at least 3% concentration for 30 min delivered enough HC, equivalent to the

animal experiment levels, in the blood without compromising the safety. However, the

consistency of H2 delivery by inhalation needs to be improved.